Approved June 1996
allergic and non-allergic rhinitis
Vancenase AQ 84 mcg Double Strength, a once-daily aqueous corticosteroid nasal spray for adults and children six years of age and over, has been approved by the FDA.
Available by prescription, Vancenase AQ 84 mcg Double Strength is indicated for the relief of symptoms of allergic and non-allergic (vasomotor) rhinitis, including sneezing, runny nose, and nasal congestion. Vancenase AQ 84 mcg Double Strength is a concentrated form of Vancenase AQ, a twice-daily formulation. The new Vancenase AQ formulation delivers 84 mcg of beclomethasone dipropionate per dose (two metered sprays, once daily), twice the amount of medication released in the same dosage of Vancenase AQ.
Clinical trials with Vancenase AQ 84 mcg Double Strength in subjects with seasonal allergic rhinitis showed that this concentrated, once-daily medication is as safe and effective in relieving the symptoms of allergic rhinitis as the original formulation. In a recent study of 194 subjects diagnosed with allergic rhinitis, Vancenase AQ 84 mcg Double Strength, administered once daily, significantly reduced nasal symptoms when compared with placebo. The incidence of side effects in subjects treated with Vancenase AQ 84 mcg Double Strength was similar to that found with placebo.
The Vancenase AQ 84 mcg Double Strength drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.